中国麻风皮肤病杂志 ›› 2018, Vol. 34 ›› Issue (12): 705-707.

• 论著 •    下一篇

Lyn抑制剂Bafetinib对恶性黑素瘤细胞株UACC62增殖和凋亡的影响

张倩倩1,2 孟现广2 黄淑红3 党宁宁2   

  1. 1 泰山医学院，山东泰安，271016 2 山东大学附属济南市中心医院皮肤科，山东济南，250013 3 山东大学齐鲁医学院基础医学院，山东济南，250012
  • 出版日期:2018-12-13 发布日期:2018-12-13
  • 通讯作者: 党宁宁，E-mail: 15318816250@ 163.com

Lyn inhibitor Bafetinib inhibits the proliferation and promotes the apoptosis of human malignant melanoma cell UACC62

ZHANG Qianqian1,2 MENG Xianguang2 HUANG Shuhong3 DANG Ningning2   

  1. 1.Taishan Medicine University, Shandong Province, Taian 271016, China; 2. Department of Dermatology, Jinan Central Hospital affiliated to Shandong University, Jinan 250013, China; 3. School of Medicine, Shandong University, Jinan 250012, China
  • Online:2018-12-13 Published:2018-12-13
  • Contact: DANG Dingning, E-mail: 15318816250@ 163.com

PDF (PC)

197

摘要： 目的：明确Lyn抑制剂Bafetinib对恶性黑素瘤细胞株UACC62增殖和凋亡的影响。方法：体外培养UACC62细胞，用不同浓度的Bafetinib处理，应用CCK-8实验和克隆形成实验检测细胞增殖能力，观察Bafetinib的效应以及是否具有剂量依赖性，并选择出合适的浓度进一步实验。Western blot检测Lyn、凋亡相关蛋白（Bax、Beclin、Bcl-2）及信号转导通路蛋白的表达。结果：Bafetinib能够抑制黑素瘤细胞UACC62的活力，并呈一定的剂量依赖性；Bafetinib处理组细胞的OD值为1.05±0.08，低于对照组的2.04±0.07 ( P＜0.05)；Bafetinib处理组细胞克隆数为49±8.53，低于对照组的288±7．68( P＜0.05)。Bafetinib处理组细胞中P-ERK、Beclin1、Bax、Bcl-2、Lyn蛋白的表达量分别是对照组的0.30，3.25, 2.23，0.53, 0.29倍( P＜0.05)。结论：Lyn抑制剂Bafetinib能够抑制恶性黑素瘤细胞UACC62的增殖，并通过ERK信号通路诱导细胞凋亡。

关键词: Lyn, Bafetinib, 黑素瘤, 增殖, 凋亡

Abstract: Objective: To determine the effects of Lyn inhibitor Bafetinib on the proliferation and apoptosis of human malignant melanoma cell UACC62. Methods: The cells were cultured in vitro, then they were treated with various concentrations and selected the suitable concentration that can advance further experiments. The proliferation of cells were detected by CCK-8 and Clone formation assays. The expression of Lyn, apoptosis-related proteins (Bcl-2, Bax, Beclin) and related-signaling pathway proteins were detected by Western blot. Results: Bafetinib inhibited the cell viability of melanoma cell UACC62 in a dose-dependent manner within a certain concentration range. The OD scores and clone numbers of UACC62 cells in Bafetinib-treated group were 1.05±0.08 and 49±8.53, which were lower than that in the control group (2.04±0.07 and 288±7.68 ) ( P＜0.05). The expression of P-ERK, Beclin1, Bax, Bcl-2 and Lyn in the experimental cells were 0.30，3.25, 2.23，0.53, 0.29 timesless or more than that in the control cells. Conclusion: Lyn inhibitor Bafetinib inhibited UACC62 cell proliferation and promoted UACC62 cell apoptosis through the ERK signaling pathway.

Key words: Lyn, Bafetinib, malignant melanoma, proliferation, apoptosis